EU-Japan Biotech & Pharma Partnering Conference 2026

16 Sept – 5 Oct 2026 | Osaka, Japan

HomeAgenda
Register
Register
Register

InvestmentUpdated on 7 September 2026

WPD Pharmaceuticals is seeking EUR 2–4 million in strategic investment to advance its lead programme, WPD401, through IND-enabling development

About

WPD Pharmaceuticals is seeking EUR 2–4 million in strategic investment to advance its lead programme, WPD401, through IND-enabling development and Phase I clinical proof of concept in recurrent glioblastoma. The investment provides exposure to a differentiated multi-targeted oncology platform with additional opportunities in blood–brain barrier delivery, theranostics and other receptor-positive solid tumors. The key near-term value inflection point is first-in-human validation of WPD401, with subsequent potential for pharma partnering, out-licensing or co-development.

Stage

  • Startup

Applies to

  • Healthcare

Organisation

WPD Pharmaceuticals SA

Company (SME/startup) / 中小企業・スタートアップ

Warszawa, Poland